Rational development of a HIV-1 gene therapy vector

被引:28
|
作者
Anson, DS
Fuller, M
机构
[1] Womens & Childrens Hosp, Dept Chem Pathol, Adelaide, SA 5006, Australia
[2] Univ Adelaide, Dept Paediat, Adelaide, SA 5005, Australia
来源
JOURNAL OF GENE MEDICINE | 2003年 / 5卷 / 10期
关键词
HIV; gene therapy; vector; optimisation;
D O I
10.1002/jgm.415
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background HIV-1 provides an attractive option as the basis for gene transfer vectors due to its ability to stably transduce non-cycling cell populations. in order to fully utilise the promise of HIV-1 as a vector it is important that the effects of viral cis sequence elements on vector function are carefully delineated. Methods In this study we have systematically evaluated the effect of various cis elements from the HIV-1 YU-2 genome that have been implicated as either affecting vector performance, or HIV-1 replication, on the efficiency of vector production (titre and infectivity). As a measure of the relative safety of vectors their propensity to inadvertently transfer the gagpol gene to transduced cells was assessed. Results Sequences that were found to increase vector titre were from the 5' end of the gag gene, from the 5' and 3' ends of the env gene, from immediately upstream of the polypurine tract, and the central polypurine tract. The substitution of the HIV-1 RRE with heterologous RNA transport elements, or the deletion of the RRE, resulted in greatly reduced vector titres. RNA analysis suggested that the role of the Rev/RRE system extends beyond simply acting as an RNA nuclear export signal. The relative safety of different vector designs was compared and an optimal construct selected. Conclusions Based on our results we have constructed a vector that is both more efficient, and has better safety characteristics, than the widely used pHR' HIV-1 vector construct. Copyright (C) 2003 John Wiley Sons, Ltd.
引用
收藏
页码:829 / 838
页数:10
相关论文
共 50 条
  • [1] Development and characterization of a triple combination gene therapy vector inhibiting HIV-1 multiplication
    Asparuhova, Maria B.
    Barde, Isabelle
    Trono, Didier
    Schranz, Karin
    Schuemperli, Daniel
    JOURNAL OF GENE MEDICINE, 2008, 10 (10): : 1059 - 1070
  • [2] Rational development of radiopharmaceuticals for HIV-1
    Lau, Chuen-Yen
    Maldarelli, Frank
    Eckelman, William C.
    Neumann, Ronald D.
    NUCLEAR MEDICINE AND BIOLOGY, 2014, 41 (04) : 299 - 308
  • [3] HIV-1 AS A VECTOR FOR GENE TRANSDUCTION
    POZNANSKY, MC
    LEVER, A
    RICHARDSON, J
    HASELTINE, WA
    SODROSKI, J
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1991, 7 (02) : 129 - 130
  • [4] Gene therapy for HIV-1
    J. Lisziewicz
    L. Galluzzi
    F. Lori
    Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2001, 44 (11) : 1071 - 1075
  • [5] HIV-1 vectors for gene therapy
    Parolin, C
    Palu, G
    MINERVA BIOTECNOLOGICA, 1997, 9 (03) : 139 - 147
  • [6] Gene therapy for HIV-1 infection
    Kohn, DB
    Sarver, N
    ANTIVIRAL CHEMOTHERAPY 4: NEW DIRECTIONS FOR CLINICAL APPLICATION AND RESEARCH, 1996, 394 : 421 - 428
  • [7] Gene therapy as a vaccine for HIV-1
    Berkhout, Ben
    Sanders, Rogier W.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (10) : 1315 - 1321
  • [8] RNAi -based gene therapy for HIV-1
    Berkhout, Ben
    HUMAN GENE THERAPY, 2014, 25 (11) : A21 - A21
  • [9] HIV-1 ZINC FINGERS - A TARGET FOR RATIONAL DRUG DEVELOPMENT
    HENDERSON, LE
    SOWDER, RC
    BESS, JW
    CASASFINET, JR
    YU, X
    FENSELAU, C
    RICE, WG
    MENDELEYEV, J
    WINK, DA
    KUN, E
    ARTHUR, LO
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 : S27 - S27
  • [10] Antibodies in HIV-1 Vaccine Development and Therapy
    Klein, Florian
    Mouquet, Hugo
    Dosenovic, Pia
    Scheid, Johannes F.
    Scharf, Louise
    Nussenzweig, Michel C.
    SCIENCE, 2013, 341 (6151) : 1199 - 1204